Skip to main content
SpringerLink
Log in

Pharmacotherapy of Thoracic Aortic Aneurysm

  • Chapter
  • First Online:
Pharmacotherapy in Aortic Disease

Part of the book series: Current Cardiovascular Therapy ((CCT,volume 7))

  • 831 Accesses

Abstract

Aortic aneurysm is defined as a permanent focal aorta dilatation. with at least a 50 % increase in diameter compared with the expected normal diameter. Thoracic aortic aneurysms (TAA) may involve one or more aortic segments (aortic root, ascending aorta, arch or descending aorta). Sixty percent of TAAs involve the aortic root and/or ascending tubular aorta, 40 % the descending aorta, 10 % the arch, and 10 % the thoracoabdominal aorta. In the ascending aorta, genetic factors are of major importance and in the descending aorta, are the risk factors for atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Braverman AC. Medical management of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg. 2013;145(3 Suppl):S2–6.

    Article  PubMed  Google Scholar 

  2. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, et al. Familial thoracic aortic aneurysms and dissections – incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg. 2006;82(4):1400–5.

    Article  PubMed  Google Scholar 

  3. Ito S, Akutsu K, Tamori Y, Sakamoto S, Yoshimuta T, Hashimoto H, et al. Differences in atherosclerotic profiles between patients with thoracic and abdominal aortic aneurysms. Am J Cardiol. 2008;101(5):696–9.

    Article  PubMed  Google Scholar 

  4. Danyi P, Elefteriades JA, Jovin IS. Medical therapy of thoracic aortic aneurysms: are we there yet? Circulation. 2011;124(13):1469–76.

    Article  PubMed  Google Scholar 

  5. Pyeritz RE. Heritable thoracic aortic disorders. Curr Opin Cardiol. 2014;29(1):97–102.

    Article  PubMed  Google Scholar 

  6. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996;62(4):417–26.

    Article  PubMed  Google Scholar 

  7. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476–85.

    Article  CAS  PubMed  Google Scholar 

  8. Pope FM, Narcisi P, Nicholls AC, Germaine D, Pals G, Richards AJ. COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture. Br J Dermatol. 1996;135(2):163–81.

    Article  CAS  PubMed  Google Scholar 

  9. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355(8):788–98.

    Article  CAS  PubMed  Google Scholar 

  10. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275–81.

    Article  CAS  PubMed  Google Scholar 

  11. Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005;112(4):513–20.

    Article  CAS  PubMed  Google Scholar 

  12. Attias D, Stheneur C, Roy C, Collod-Beroud G, Detaint D, Faivre L, et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation. 2009;120(25):2541–9.

    Article  CAS  PubMed  Google Scholar 

  13. Aubart M, Gobert D, Aubart-Cohen F, Detaint D, Hanna N, d’Indya H, et al. Early-onset osteoarthritis, charcot-marie-tooth like neuropathy, autoimmune features, multiple arterial aneurysms and dissections: an unrecognized and life threatening condition. PLoS One. 2014;9(5):e96387.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012;44(8):916–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007;39(12):1488–93.

    Article  CAS  PubMed  Google Scholar 

  16. Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, et al. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet. 2009;84(5):617–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006;38(3):343–9.

    Article  CAS  PubMed  Google Scholar 

  18. Sievers HH, Sievers HL. Aortopathy in bicuspid aortic valve disease – genes or hemodynamics? or Scylla and Charybdis? Eur J Cardiothorac Surg. 2011;39(6):803–4.

    Article  PubMed  Google Scholar 

  19. Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg. 2007;133(5):1226–33.

    Article  PubMed  Google Scholar 

  20. Detaint D, Michelena HI, Nkomo VT, Vahanian A, Jondeau G, Sarano ME. Aortic dilatation patterns and rates in adults with bicuspid aortic valves: a comparative study with Marfan syndrome and degenerative aortopathy. Heart. 2014;100(2):126–34.

    Article  PubMed  Google Scholar 

  21. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey Jr DE, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121(13):e266–369.

    Article  PubMed  Google Scholar 

  22. Fernandez B, Duran AC, Fernandez-Gallego T, Fernandez MC, Such M, Arque JM, et al. Bicuspid aortic valves with different spatial orientations of the leaflets are distinct etiological entities. J Am Coll Cardiol. 2009;54(24):2312–8.

    Article  PubMed  Google Scholar 

  23. Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner syndrome. Circulation. 2007;116(15):1663–70.

    Article  PubMed  Google Scholar 

  24. Cabanes L, Chalas C, Christin-Maitre S, Donadille B, Felten ML, Gaxotte V, et al. Turner syndrome and pregnancy: clinical practice. Recommendations for the management of patients with Turner syndrome before and during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):18–24.

    Article  PubMed  Google Scholar 

  25. Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011;306(10):1104–12.

    Article  CAS  PubMed  Google Scholar 

  26. Barbour JR, Spinale FG, Ikonomidis JS. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res. 2007;139(2):292–307.

    Article  CAS  PubMed  Google Scholar 

  27. Borges LF, Touat Z, Leclercq A, Zen AA, Jondeau G, Franc B, et al. Tissue diffusion and retention of metalloproteinases in ascending aortic aneurysms and dissections. Hum Pathol. 2009;40(3):306–13.

    Article  CAS  PubMed  Google Scholar 

  28. Touat Z, Lepage L, Ollivier V, Nataf P, Hvass U, Labreuche J, et al. Dilation-dependent activation of platelets and prothrombin in human thoracic ascending aortic aneurysm. Arterioscler Thromb Vasc Biol. 2008;28(5):940–6.

    Article  CAS  PubMed  Google Scholar 

  29. Borges LF, Gomez D, Quintana M, Touat Z, Jondeau G, Leclercq A, et al. Fibrinolytic activity is associated with presence of cystic medial degeneration in aneurysms of the ascending aorta. Histopathology. 2010;57(6):917–32.

    Article  PubMed  Google Scholar 

  30. Meilhac O, Ho-Tin-Noe B, Houard X, Philippe M, Michel JB, Angles-Cano E. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J. 2003;17(10):1301–3.

    CAS  PubMed  Google Scholar 

  31. Michel JB. Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol. 2003;23(12):2146–54.

    Article  CAS  PubMed  Google Scholar 

  32. Plow EF, Hoover-Plow J. The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med. 2004;14(5):180–6.

    Article  CAS  PubMed  Google Scholar 

  33. Nagaoka K, Sadamatsu K, Yamawaki T, Shikada T, Sagara S, Ohe K, et al. Fibrinogen/fibrin degradation products in acute aortic dissection. Intern Med. 2010;49(18):1943–7.

    Article  CAS  PubMed  Google Scholar 

  34. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Gomez D, Al Haj Zen A, Borges LF, Philippe M, Gutierrez PS, Jondeau G, et al. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. J Pathol. 2009;218(1):131–42.

    Article  CAS  PubMed  Google Scholar 

  36. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet. 2004;36(8):855–60.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Gomez D, Coyet A, Ollivier V, Jeunemaitre X, Jondeau G, Michel JB, et al. Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. Cardiovasc Res. 2011;89(2):446–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451–96.

    Article  PubMed  Google Scholar 

  39. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73(1):17–27; discussion −8.

    Article  PubMed  Google Scholar 

  40. Evangelista A. Imaging aortic aneurysmal disease. Heart. 2014;100(12):909–15.

    Article  PubMed  Google Scholar 

  41. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg. 1997;113(3):476–91; discussion 89–91.

    Article  CAS  PubMed  Google Scholar 

  42. Bickerstaff LK, Pairolero PC, Hollier LH, Melton LJ, Van Peenen HJ, Cherry KJ, et al. Thoracic aortic aneurysms: a population-based study. Surgery. 1982;92(6):1103–8.

    CAS  PubMed  Google Scholar 

  43. Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin. 1999;17(4):615–35, vii.

    Article  CAS  PubMed  Google Scholar 

  44. MacDougall JD, Tuxen D, Sale DG, Moroz JR, Sutton JR. Arterial blood pressure response to heavy resistance exercise. J Appl Physiol (1985). 1985;58(3):785–90.

    CAS  Google Scholar 

  45. Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol. 2005;45(8):1364–7.

    Article  PubMed  Google Scholar 

  46. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol. 2005;45(8):1340–5.

    Article  PubMed  Google Scholar 

  47. Keane MG, Pyeritz RE. Medical management of Marfan syndrome. Circulation. 2008;117(21):2802–13.

    Article  PubMed  Google Scholar 

  48. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med. 1994;330(19):1335–41.

    Article  CAS  PubMed  Google Scholar 

  49. Ladouceur M, Fermanian C, Lupoglazoff JM, Edouard T, Dulac Y, Acar P, et al. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol. 2007;99(3):406–9.

    Article  CAS  PubMed  Google Scholar 

  50. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;2.

    Google Scholar 

  51. Gallo EM, Loch DC, Habashi JP, Calderon JF, Chen Y, Bedja D, et al. Angiotensin II-dependent TGF-beta signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest. 2014;124(1):448–60.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.

    Article  CAS  PubMed  Google Scholar 

  53. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108(6):684–90.

    Article  CAS  PubMed  Google Scholar 

  54. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110(11):1456–62.

    Article  CAS  PubMed  Google Scholar 

  55. Jondeau G, Boutouyrie P, Lacolley P, Laloux B, Dubourg O, Bourdarias JP, et al. Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome. Circulation. 1999;99(20):2677–81.

    Article  CAS  PubMed  Google Scholar 

  56. Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, et al. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet. 2008;9:283–302.

    Article  CAS  PubMed  Google Scholar 

  57. Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376(9751):1476–84.

    Article  CAS  PubMed  Google Scholar 

  58. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol. 2005;95(9):1125–7.

    Article  CAS  PubMed  Google Scholar 

  59. Riccioni G. Ivabradine: from molecular basis to clinical effectiveness. Adv Ther. 2010;27(3):160–7.

    Article  CAS  PubMed  Google Scholar 

  60. Fazel SS, Mallidi HR, Lee RS, Sheehan MP, Liang D, Fleischman D, et al. The aortopathy of bicuspid aortic valve disease has distinctive patterns and usually involves the transverse aortic arch. J Thorac Cardiovasc Surg. 2008;135(4):901–7, 7.e1–2.

    Article  PubMed  Google Scholar 

  61. Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg. 2002;35(1):72–9.

    Article  Google Scholar 

  62. Lindholt JS, Henneberg EW, Juul S, Fasting H. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol. 1999;18(1):52–7.

    CAS  PubMed  Google Scholar 

  63. Leach SD, Toole AL, Stern H, DeNatale RW, Tilson MD. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg. 1988;123(5):606–9.

    Article  CAS  PubMed  Google Scholar 

  64. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case–control study. Lancet. 2006;368(9536):659–65.

    Article  CAS  PubMed  Google Scholar 

  65. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg. 2010;52(1):1–4.

    Article  PubMed  Google Scholar 

  66. Delbosc S, Alsac JM, Journe C, Louedec L, Castier Y, Bonnaure-Mallet M, et al. Porphyromonas gingivalis participates in pathogenesis of human abdominal aortic aneurysm by neutrophil activation. Proof of concept in rats. PLoS One. 2011;6(4):e18679.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Jackson V, Olsson T, Kurtovic S, Folkersen L, Paloschi V, Wagsater D, et al. Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2012;144(2):459–66.

    Article  CAS  PubMed  Google Scholar 

  68. Boyum J, Fellinger EK, Schmoker JD, Trombley L, McPartland K, Ittleman FP, et al. Matrix metalloproteinase activity in thoracic aortic aneurysms associated with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc Surg. 2004;127(3):686–91.

    Article  CAS  PubMed  Google Scholar 

  69. Yang HH, Kim JM, Chum E, van Breemen C, Chung AW. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. J Thorac Cardiovasc Surg. 2010;140(2):305–12.e2.

    Article  CAS  PubMed  Google Scholar 

  70. Xiong W, Knispel RA, Dietz HC, Ramirez F, Baxter BT. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg. 2008;47(1):166–72; discussion 72.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Chung AW, Yang HH, Radomski MW, van Breemen C. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and −9. Circ Res. 2008;102(8):e73–85.

    Article  CAS  PubMed  Google Scholar 

  72. McLoughlin D, McGuinness J, Byrne J, Terzo E, Huuskonen V, McAllister H, et al. Pravastatin reduces Marfan aortic dilation. Circulation. 2011;124(11 Suppl):S168–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre National Maladies Rares Syndrome de Marfan et apparentés, INSERM U1148 (LVTS), Université Paris 7, AP-HP Hopital Bichat, Paris, 75018, France

    Guillaume Jondeau

  2. Centre National Maladies Rares Syndrome de Marfan et apparentés, INSERM U1148 (LVTS), AP-HP Hopital Bichat, Paris, 75018, France

    Olivier Milleron & Claire Bouleti

  3. Centre National Maladies Rares Syndrome de Marfan et apparentés, INSERM U1148 (LVTS), Hopital Bichat, Paris, 75018, France

    Jean-Baptiste Michel

Authors
  1. Guillaume Jondeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Milleron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claire Bouleti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Baptiste Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guillaume Jondeau .

Editor information

Editors and Affiliations

  1. Imaging Cardiac Department Aortic Diseases Unit, Vall d’hebrón University Hospital, Barcelona, Spain

    Arturo Evangelista

  2. Heart Center Rostock, Rostock School of Medicine University Hospital Rostock, Rostock, Germany

    Christoph A. Nienaber

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Jondeau, G., Milleron, O., Bouleti, C., Michel, JB. (2015). Pharmacotherapy of Thoracic Aortic Aneurysm. In: Evangelista, A., Nienaber, C. (eds) Pharmacotherapy in Aortic Disease. Current Cardiovascular Therapy, vol 7. Springer, Cham. https://doi.org/10.1007/978-3-319-09555-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-09555-4_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-09554-7

  • Online ISBN: 978-3-319-09555-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation